Fennec Pharmaceuticals Inc

FENC remains in a high-confidence Stage 2 advancing uptrend with an active momentum breakout confirming medium-term bullish structure, but price is currently extended above rising EMAs with overbought RSI and options score, making short-term execution unfavorable; deferred entries on a healthy pullback into support are advised.

• ↑Q2 revenue rose 78% YoY to $17.1 M with net income of $1.97 M
• ↑Non-GAAP EBITDA turned positive at $2.8 M vs a $1.2 M loss prior year
• ↓Negative earnings yield and low book-to-price suggest overvaluation